Re: early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial.
Testa
Luca
L
Van Gaal
William
W
Biondi-Zoccai
Giuseppe
G
Abbate
Antonio
A
Trotta
Graziana
G
Agostoni
Pierfrancesco
P
D000925:Anticoagulants / Q000009:adverse effects; D001384:Azetidines / Q000009:adverse effects; D001596:Benzylamines / Q000009:adverse effects; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000378:metabolism*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood*; D017202:Myocardial Ischemia / Q000097:blood*; D010446:Peptide Fragments / Q000378:metabolism; D011498:Protein Precursors / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D001779:Blood Coagulation Factors; D010446:Peptide Fragments; D011498:Protein Precursors; C426686:ximelagatran; C029733:prothrombin fragment 1; C044183:prothrombin fragment 2; D011516:Prothrombin